

## HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use KINRIX safely and effectively. See full prescribing information for KINRIX.

**KINRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine) injectable suspension, for intramuscular use**

Initial U.S. Approval: 2008

### INDICATIONS AND USAGE

A single dose of KINRIX is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine series and the fourth dose in the inactivated poliovirus vaccine (IPV) series in children aged 4 through 6 years (prior to the seventh birthday) whose previous DTaP vaccine doses have been with INFANRIX and/or PEDIARIX for the first 3 doses and INFANRIX for the fourth dose. (1)

### DOSAGE AND ADMINISTRATION

**For intramuscular use. (2)**

Administer a single 0.5 mL dose. (2.2)

### DOSAGE FORMS AND STRENGTHS

Injectable suspension. Each dose is 0.5 mL. (3)

### CONTRAINDICATIONS

- Severe allergic reaction (e.g., anaphylaxis) after a previous dose of any diphtheria toxoid-, tetanus toxoid-, pertussis- or poliovirus-containing vaccine, or to any component of KINRIX, including neomycin and polymyxin B. (4.1)
- Encephalopathy within 7 days of administration of a previous pertussis-containing vaccine. (4.2)

- Progressive neurologic disorders. (4.3)

### WARNINGS AND PRECAUTIONS

- If Guillain-Barré syndrome occurs within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the decision to give KINRIX should be based on potential benefits and risks. (5.1)
- Syncope (fainting) can occur in association with administration of injectable vaccines, including KINRIX. Procedures should be in place to avoid injury from fainting. (5.2)
- If temperature  $\geq 105^{\circ}\text{F}$ , collapse or shock-like state, or persistent, inconsolable crying lasting  $\geq 3$  hours have occurred within 48 hours after receipt of a pertussis-containing vaccine, or if seizures have occurred within 3 days after receipt of a pertussis-containing vaccine, the decision to give KINRIX should be based on potential benefits and risks. (5.3)
- For children at higher risk for seizures, an antipyretic may be administered at the time of vaccination with KINRIX. (5.4)

### ADVERSE REACTIONS

- The most frequently reported solicited local reaction ( $>50\%$ ) was injection site pain. Other common solicited local reactions ( $\geq 25\%$ ) were redness, increase in arm circumference, and swelling. (6.1)
- Common solicited general adverse reactions ( $\geq 15\%$ ) were drowsiness, fever ( $\geq 99.5^{\circ}\text{F}$ ), and loss of appetite. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or VAERS at 1-800-822-7967 or [www.vaers.hhs.gov](http://www.vaers.hhs.gov).

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 5/2026

## FULL PRESCRIBING INFORMATION: CONTENTS\*

### 1 INDICATIONS AND USAGE

### 2 DOSAGE AND ADMINISTRATION

- 2.1 Preparation for Administration
- 2.2 Recommended Dose and Schedule

### 3 DOSAGE FORMS AND STRENGTHS

### 4 CONTRAINDICATIONS

- 4.1 Hypersensitivity
- 4.2 Encephalopathy
- 4.3 Progressive Neurologic Disorder

### 5 WARNINGS AND PRECAUTIONS

- 5.1 Guillain-Barré Syndrome
- 5.2 Syncope
- 5.3 Adverse Reactions following Prior Pertussis Vaccination
- 5.4 Children at Risk for Seizures
- 5.5 Preventing and Managing Allergic Reactions
- 5.6 Altered Immunocompetence

### 6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience

### 8 USE IN SPECIFIC POPULATIONS

- 8.4 Pediatric Use

### 11 DESCRIPTION

### 12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action

### 13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

### 14 CLINICAL STUDIES

- 14.1 Immunological Evaluation
- 14.2 Concomitant Vaccine Administration

### 15 REFERENCES

### 16 HOW SUPPLIED/STORAGE AND HANDLING

### 17 PATIENT COUNSELING INFORMATION

\*Sections or subsections omitted from the full prescribing information are not listed.

## FULL PRESCRIBING INFORMATION

### 1 INDICATIONS AND USAGE

A single dose of KINRIX is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine series and the fourth dose in the inactivated poliovirus vaccine (IPV) series in children aged 4 through 6 years (prior to the seventh birthday) whose previous DTaP vaccine doses have been with INFANRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) and/or PEDIARIX [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine] for the first 3 doses and INFANRIX for the fourth dose.

### 2 DOSAGE AND ADMINISTRATION

**For intramuscular use.**

## **2.1 Preparation for Administration**

Shake vigorously to obtain a homogeneous, turbid, white suspension. Do not use if resuspension does not occur with vigorous shaking. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions exists, the vaccine should not be administered.

Administer intramuscularly.

## **2.2 Recommended Dose and Schedule**

Administer a single 0.5 mL dose intramuscularly.

KINRIX may be used for the fifth dose in the DTaP immunization series and the fourth dose in the IPV immunization series in children aged 4 through 6 years (prior to the seventh birthday) whose previous DTaP vaccine doses have been with INFANRIX and/or PEDIARIX for the first 3 doses and INFANRIX for the fourth dose [see *Indications and Usage (1)*].

## **3 DOSAGE FORMS AND STRENGTHS**

KINRIX is an injectable suspension. Each dose is 0.5 mL.

## **4 CONTRAINDICATIONS**

### **4.1 Hypersensitivity**

KINRIX is contraindicated in individuals with a known history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any diphtheria toxoid-, tetanus toxoid-, pertussis- or poliovirus-containing vaccine, or to any component of KINRIX, including neomycin and polymyxin B [see *Description (11)*]. Because of the uncertainty as to which component of the vaccine might be responsible, no further vaccination with any of these components should be given. Alternatively, such individuals may be referred to an allergist for evaluation if immunization with any of these components is considered.

### **4.2 Encephalopathy**

Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of administration of a previous dose of a pertussis-containing vaccine that is not attributable to another identifiable cause is a contraindication to administration of any pertussis-containing vaccine, including KINRIX.

### **4.3 Progressive Neurologic Disorder**

Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy, is a contraindication to administration of any pertussis-containing vaccine, including KINRIX. Pertussis vaccine should not be administered to individuals with such conditions until a treatment regimen has been established and the condition has stabilized.

## **5 WARNINGS AND PRECAUTIONS**

### **5.1 Guillain-Barré Syndrome**

If Guillain-Barré syndrome occurs within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the decision to give any tetanus toxoid-containing vaccine, including KINRIX, should be based on careful

consideration of the potential benefits and possible risks. When a decision is made to withhold tetanus toxoid, other available vaccines should be given, as indicated.

## **5.2 Syncope**

Syncope (fainting) can occur in association with administration of injectable vaccines, including KINRIX. Procedures should be in place to avoid injury from fainting.

## **5.3 Adverse Reactions following Prior Pertussis Vaccination**

If any of the following reactions occur in temporal relation to receipt of a pertussis-containing vaccine, the decision to give any pertussis-containing vaccine, including KINRIX, should be based on careful consideration of the potential benefits and possible risks:

- Temperature of  $\geq 40.5^{\circ}\text{C}$  ( $105^{\circ}\text{F}$ ) within 48 hours not due to another identifiable cause;
- Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours;
- Persistent, inconsolable crying lasting  $\geq 3$  hours, occurring within 48 hours;
- Seizures with or without fever occurring within 3 days.

When a decision is made to withhold pertussis vaccination, other available vaccines should be given, as indicated.

## **5.4 Children at Risk for Seizures**

For children at higher risk for seizures than the general population, an appropriate antipyretic may be administered at the time of vaccination with a pertussis-containing vaccine, including KINRIX, and for the ensuing 24 hours to reduce the possibility of postvaccination fever.

## **5.5 Preventing and Managing Allergic Reactions**

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of KINRIX.

## **5.6 Altered Immunocompetence**

As with any vaccine, if administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the expected immune response may not be obtained. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune response to KINRIX.

# **6 ADVERSE REACTIONS**

## **6.1 Clinical Trials Experience**

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared with rates in the clinical trials of another vaccine and may not reflect the rates observed in practice.

A total of 4,013 children were vaccinated with a single dose of KINRIX in 4 clinical trials. Of these, 381 children received a non-U.S. formulation of KINRIX (containing  $\leq 2.5$  mg 2-phenoxyethanol per dose as preservative).

The primary study (Study 048), conducted in the United States, was a randomized, controlled clinical trial in which children aged 4 to 6 years were vaccinated with KINRIX (n = 3,156) or control vaccines (INFANRIX and IPOL vaccine [IPV, Sanofi Pasteur SA]; n = 1,053) as a fifth DTaP vaccine dose following 4 doses of INFANRIX and as a fourth IPV dose following 3 doses of IPOL. Participants also received the second dose of U.S.-licensed measles, mumps, and rubella (MMR) vaccine (Merck & Co., Inc.) administered concomitantly, at separate sites.

Data on adverse events were collected by parents/guardians using standardized forms for 4 consecutive days following vaccination with KINRIX or control vaccines (i.e., day of vaccination and the next 3 days). The reported frequencies of solicited local reactions and general adverse reactions in Study 048 are presented in Table 1.

In 3 studies (Studies 046, 047, and 048), children were monitored for unsolicited adverse events, including serious adverse events that occurred in the 31-day period following vaccination, and in 2 studies (Studies 047 and 048), parents/guardians were actively queried about changes in the child's health status, including the occurrence of serious adverse events, through 6 months postvaccination.

**Table 1. Percentage of Children Aged 4 to 6 Years Reporting Solicited Local or General Adverse Reactions within 4 Days of Vaccination<sup>a</sup> with KINRIX or Separate Concomitant Administration of INFANRIX and IPV when Coadministered with MMR Vaccine (Study 048) (Total Vaccinated Cohort)**

<b>Adverse Reaction</b>	<b>KINRIX</b>	<b>INFANRIX + IPV</b>
<b>Local<sup>b</sup></b>	<b>n = 3,121-3,128</b>	<b>n = 1,039-1,043</b>
Pain, any	57 <sup>c</sup>	53
Pain, Grade 2 or 3 <sup>d</sup>	14	12
Pain, Grade 3 <sup>d</sup>	2 <sup>c</sup>	1
Redness, any	37	37
Redness, ≥50 mm	18	20
Redness, ≥110 mm	3	4
Arm circumference increase, any	36	38
Arm circumference increase, >20 mm	7	7
Arm circumference increase, >30 mm	2	3
Swelling, any	26	27
Swelling, ≥50 mm	10	12
Swelling, ≥110 mm	1	2
<b>General</b>	<b>n = 3,037-3,120</b>	<b>n = 993-1,036</b>
Drowsiness, any	19	18
Drowsiness, Grade 3 <sup>e</sup>	1	1
Fever, ≥99.5°F	16	15
Fever, >100.4°F	7 <sup>c</sup>	4
Fever, >102.2°F	1	1
Fever, >104°F	0	0
Loss of appetite, any	16	16
Loss of appetite, Grade 3 <sup>f</sup>	1	1

IPV = Inactivated poliovirus vaccine (Sanofi Pasteur SA); MMR = Measles, mumps, and rubella vaccine (Merck & Co., Inc.).

Total Vaccinated Cohort = All vaccinated participants for whom safety data were available.

n = Number of children with evaluable data for the reactions listed.

<sup>a</sup> Within 4 days of vaccination defined as day of vaccination and the next 3 days.

<sup>b</sup> Local reactions at the injection site for KINRIX or INFANRIX.

<sup>c</sup> Statistically higher than comparator group ( $P < 0.05$ ).

<sup>d</sup> Grade 2 defined as painful when the limb was moved; Grade 3 defined as preventing normal daily activities.

<sup>e</sup> Grade 3 defined as preventing normal daily activities.

<sup>f</sup> Grade 3 defined as not eating at all.

In Study 048, KINRIX was non-inferior to INFANRIX with regard to swelling that involved >50% of the injected upper arm length and that was associated with a >30 mm increase in mid-upper arm circumference within 4 days following vaccination (upper limit of 2-sided 95% Confidence Interval for difference in percentage of KINRIX [0.6%, n = 20] minus INFANRIX [1.0%, n = 11] ≤2%).

## Serious Adverse Events

Within the 31-day period following study vaccination in 3 studies (Studies 046, 047, and 048) in which all participants received concomitant MMR vaccine (U.S.-licensed MMR vaccine [Merck & Co., Inc.] in Studies 047 and 048, non—U.S.-licensed MMR vaccine in Study 046), 3 participants (0.1% [3/3,537]) who received KINRIX reported serious adverse events (dehydration and hypernatremia; cerebrovascular accident; dehydration and gastroenteritis) and 4 participants (0.3% [4/1,434]) who received INFANRIX and inactivated poliovirus vaccine (Sanofi Pasteur SA) reported serious adverse events (cellulitis, constipation, foreign body trauma, fever without identified etiology).

## **6.2 Postmarketing Experience**

In addition to reports in clinical trials for KINRIX, the following adverse reactions have been identified during postapproval use of KINRIX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccination.

### General Disorders and Administration Site Conditions

Injection site vesicles.

### Nervous System Disorders

Syncope.

### Skin and Subcutaneous Tissue Disorders

Pruritus.

Additional adverse reactions reported following postmarketing use of INFANRIX, for which a causal relationship to vaccination is plausible, are: Allergic reactions, including anaphylactoid reactions, anaphylaxis, angioedema, and urticaria; apnea; collapse or shock-like state (hypotonic-hyporesponsive episode); convulsions (with or without fever); lymphadenopathy; and thrombocytopenia.

## **8 USE IN SPECIFIC POPULATIONS**

### **8.4 Pediatric Use**

Safety and effectiveness of KINRIX in children younger than 4 years and children aged 7 to 16 years have not been evaluated. KINRIX is not approved for use in persons in these age groups.

## **11 DESCRIPTION**

KINRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine) is a noninfectious, sterile, injectable suspension for intramuscular use. Each 0.5 mL dose is formulated to contain 25 Lf of diphtheria toxoid, 10 Lf of tetanus toxoid, 25 mcg of inactivated pertussis toxin (PT), 25 mcg of filamentous hemagglutinin (FHA), 8 mcg of pertactin (69 kiloDalton outer membrane protein), 40 D-antigen Units (DU) of Type 1 poliovirus (Mahoney), 8 DU of Type 2 poliovirus (MEF-1), and 32 DU of Type 3 poliovirus (Saukett). The diphtheria, tetanus, and pertussis components of KINRIX are the same as those in INFANRIX and PEDIARIX and the poliovirus component is the same as that in PEDIARIX.

The diphtheria toxin is produced by growing *Corynebacterium diphtheriae* (*C. diphtheriae*) in Fenton medium containing a bovine extract. Tetanus toxin is produced by growing *Clostridium tetani* (*C. tetani*) in a modified

Latham medium derived from bovine casein. The bovine materials used in these extracts are sourced from countries which the United States Department of Agriculture (USDA) has determined neither have nor are at risk of bovine spongiform encephalopathy (BSE). Both toxins are detoxified with formaldehyde, concentrated by ultrafiltration, and purified by precipitation, dialysis, and sterile filtration.

The acellular pertussis antigens (PT, FHA, and pertactin) are isolated from *Bordetella pertussis* (*B. pertussis*) culture grown in modified Stainer-Scholte liquid medium. PT and FHA are isolated from the fermentation broth; pertactin is extracted from the cells by heat treatment and flocculation. The antigens are purified in successive chromatographic and precipitation steps. PT is detoxified using glutaraldehyde and formaldehyde. FHA and pertactin are treated with formaldehyde.

Diphtheria and tetanus toxoids and pertussis antigens (inactivated PT, FHA, and pertactin) are individually adsorbed onto aluminum hydroxide.

The inactivated poliovirus component of KINRIX is an enhanced potency component. Each of the 3 strains of poliovirus is individually grown in VERO cells, a continuous line of monkey kidney cells, cultivated on microcarriers. Calf serum and lactalbumin hydrolysate are used during VERO cell culture and/or virus culture. Calf serum is sourced from countries the USDA has determined neither have nor are at risk of BSE. After clarification, each viral suspension is purified by ultrafiltration, diafiltration, and successive chromatographic steps, and inactivated with formaldehyde. The 3 purified viral strains are then pooled to form a trivalent concentrate.

Diphtheria and tetanus toxoid potency is determined by measuring the amount of neutralizing antitoxin in previously immunized guinea pigs. The potency of the acellular pertussis components (inactivated PT, FHA, and pertactin) is determined by enzyme-linked immunosorbent assay (ELISA) on sera from previously immunized mice. The potency of the inactivated poliovirus component is determined by using the D-antigen ELISA and by a poliovirus-neutralizing cell culture assay on sera from previously immunized rats.

Each 0.5 mL dose contains aluminum hydroxide as adjuvant (formulated to contain 0.5 mg aluminum) and  $\leq 4.4$  mg of sodium chloride. The aluminum content is measured by assay. Each dose also contains  $\leq 100$  mcg of residual formaldehyde and  $\leq 100$  mcg of polysorbate 80 (Tween 80). Neomycin sulfate and polymyxin B sulfate are used in the poliovirus vaccine manufacturing process and may be present in the final vaccine at  $\leq 0.05$  ng neomycin and  $\leq 0.01$  ng polymyxin B per dose.

The tip cap and rubber plunger stopper of the prefilled syringe are not made with natural rubber latex.

KINRIX does not contain a preservative.

## **12 CLINICAL PHARMACOLOGY**

### **12.1 Mechanism of Action**

#### Diphtheria

Diphtheria is an acute toxin-mediated infectious disease caused by toxigenic strains of *C. diphtheriae*. Protection against disease is due to the development of neutralizing antibodies to the diphtheria toxin. A serum diphtheria antitoxin level of 0.01 IU/mL is the lowest level giving some degree of protection; a level of 0.1 IU/mL is regarded as protective.<sup>1</sup>

## Tetanus

Tetanus is an acute toxin-mediated disease caused by a potent exotoxin released by *C. tetani*. Protection against disease is due to the development of neutralizing antibodies to the tetanus toxin. A serum tetanus antitoxin level of at least 0.01 IU/mL, measured by neutralization assays, is considered the minimum protective level.<sup>2,3</sup> A level of  $\geq 0.1$  IU/mL is considered protective.<sup>4</sup>

## Pertussis

Pertussis (whooping cough) is a disease of the respiratory tract caused by *B. pertussis*. The role of the different components produced by *B. pertussis* in either the pathogenesis of, or the immunity to, pertussis is not well understood. There is no well-established serological correlate of protection for pertussis. The efficacy of the pertussis component of KINRIX was determined in clinical trials of INFANRIX administered as a 3-dose series in infants (see INFANRIX prescribing information).

## Poliomyelitis

Poliovirus is an enterovirus that belongs to the picornavirus family. Three serotypes of poliovirus have been identified (Types 1, 2, and 3). Neutralizing antibodies against the 3 poliovirus serotypes are recognized as conferring protection against poliomyelitis disease.<sup>5</sup>

## **13 NONCLINICAL TOXICOLOGY**

### **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

KINRIX has not been evaluated for carcinogenic or mutagenic potential or for impairment of fertility.

## **14 CLINICAL STUDIES**

### **14.1 Immunological Evaluation**

In a U.S. multicenter study (Study 048), 4,209 children were randomized in a 3:1 ratio to receive either KINRIX or INFANRIX and IPV (Sanofi Pasteur SA) administered concomitantly at separate sites. Participants also received MMR vaccine (Merck & Co., Inc.) administered concomitantly at a separate site. Participants were children aged 4 through 6 years who previously received 4 doses of INFANRIX, 3 doses of IPV, and 1 dose of MMR vaccine. Among participants in both vaccine groups combined, 49.6% were female; 45.6% of participants were White, 18.8% Hispanic, 13.6% Asian, 7.0% Black, and 15.0% were of other racial/ethnic groups.

Levels of antibodies to the diphtheria, tetanus, pertussis (PT, FHA, and pertactin), and poliovirus antigens were measured in sera obtained immediately prior to vaccination and 1 month (range: 31 to 48 days) after vaccination (Table 2). The co-primary immunogenicity endpoints were anti-diphtheria toxoid, anti-tetanus toxoid, anti-PT, anti-FHA, and anti-pertactin booster responses, and anti-poliovirus Type 1, Type 2, and Type 3 geometric mean antibody titers (GMTs) 1 month after vaccination. KINRIX was shown to be non-inferior to INFANRIX and IPV administered separately, in terms of booster responses to DTaP antigens and postvaccination GMTs for anti-poliovirus antibodies (Table 2).

**Table 2. Prevaccination Antibody Levels and Postvaccination<sup>a</sup> Antibody Responses following KINRIX Compared with Separate Concomitant Administration of INFANRIX and IPV in Children Aged 4 to 6 Years when Coadministered with MMR Vaccine (Study 048) (ATP Cohort for Immunogenicity)**

	<b>KINRIX n = 787-851</b>	<b>INFANRIX + IPV n = 237-262</b>
<b>Anti-diphtheria Toxoid</b>		
Prevaccination % $\geq 0.1$ IU/mL (95% CI) <sup>b</sup>	87.7 (85.3, 89.9)	85.5 (80.6, 89.5)
Postvaccination % $\geq 0.1$ IU/mL (95% CI) <sup>b</sup>	100 (99.6, 100)	100 (98.6, 100)
% Booster Response (95% CI) <sup>c</sup>	99.5 (98.8, 99.9) <sup>d</sup>	100 (98.6, 100)
<b>Anti-tetanus Toxoid</b>		
Prevaccination % $\geq 0.1$ IU/mL (95% CI) <sup>b</sup>	87.8 (85.4, 90.0)	88.2 (83.6, 91.8)
Postvaccination % $\geq 0.1$ IU/mL (95% CI) <sup>b</sup>	100 (99.6, 100)	100 (98.6, 100)
% Booster Response (95% CI) <sup>c</sup>	96.7 (95.2, 97.8) <sup>d</sup>	93.9 (90.2, 96.5)
<b>Anti-PT</b>		
% Booster Response (95% CI) <sup>c</sup>	92.2 (90.2, 94.0) <sup>d</sup>	92.6 (88.7, 95.5)
<b>Anti-FHA</b>		
% Booster Response (95% CI) <sup>c</sup>	95.4 (93.7, 96.7) <sup>d</sup>	96.2 (93.1, 98.1)
<b>Anti-pertactin</b>		
% Booster Response (95% CI) <sup>c</sup>	97.8 (96.5, 98.6) <sup>d</sup>	96.9 (94.1, 98.7)
<b>Anti-poliovirus 1</b>		
Prevaccination % $\geq 1:8$ (95% CI) <sup>b</sup>	88.3 (85.9, 90.4)	85.1 (80.1, 89.2)
Postvaccination % $\geq 1:8$ (95% CI) <sup>b</sup>	99.9 (99.3, 100)	100 (98.5, 100)
Postvaccination GMT (95% CI)	2,127 (1,976, 2,290) <sup>f</sup>	1,685 (1,475, 1,925)
<b>Anti-poliovirus 2</b>		
Prevaccination % $\geq 1:8$ (95% CI) <sup>b</sup>	91.8 (89.7, 93.6)	87.0 (82.3, 90.8)
Postvaccination % $\geq 1:8$ (95% CI) <sup>b</sup>	100 (99.6, 100)	100 (98.5, 100)
Postvaccination GMT (95% CI)	2,265 (2,114, 2,427) <sup>f</sup>	1,818 (1,606, 2,057)
<b>Anti-poliovirus 3</b>		
Prevaccination % $\geq 1:8$ (95% CI) <sup>b</sup>	84.7 (82.0, 87.0)	85.0 (80.1, 89.1)
Postvaccination % $\geq 1:8$ (95% CI) <sup>b</sup>	100 (99.5, 100)	100 (98.5, 100)
Postvaccination GMT (95% CI)	3,588 (3,345, 3,849) <sup>f</sup>	3,365 (2,961, 3,824)

ATP = According-to-protocol; CI = Confidence Interval; GMT = Geometric mean antibody titer;

IPV = Inactivated poliovirus vaccine (Sanofi Pasteur SA); MMR = Measles, mumps, and rubella vaccine (Merck & Co., Inc.).

n = Number of participants with available results.

<sup>a</sup> One-month blood sampling, range 31 to 48 days.

<sup>b</sup> Seroprotection defined as anti-diphtheria toxoid and anti-tetanus toxoid antibody concentrations  $\geq 0.1$  IU/mL by ELISA and as anti-poliovirus Type 1, Type 2, and Type 3 antibody titer  $\geq 1:8$  by micro-neutralization assay for poliovirus.

<sup>c</sup> Booster response: In participants with prevaccination  $< 0.1$  IU/mL, postvaccination concentration  $\geq 0.4$  IU/mL. In participants with prevaccination concentration  $\geq 0.1$  IU/mL, an increase of at least 4 times the prevaccination concentration.

<sup>d</sup> KINRIX was non-inferior to INFANRIX + IPV based on booster response rates (upper limit of 2-sided 95% CI on the difference of INFANRIX + IPV minus KINRIX  $\leq 10\%$ ).

<sup>e</sup> Booster response: In participants with prevaccination  $< 5$  EL.U./mL, postvaccination concentration  $\geq 20$  EL.U./mL. In participants with prevaccination  $\geq 5$  EL.U./mL and  $< 20$  EL.U./mL, an increase of at least 4 times the prevaccination concentration. In participants with prevaccination  $\geq 20$  EL.U./mL, an increase of at least 2 times the prevaccination concentration.

<sup>f</sup> KINRIX was non-inferior to INFANRIX + IPV based on postvaccination anti-poliovirus antibody GMTs adjusted for baseline titer (upper limit of 2-sided 95% CI for the GMT ratio [INFANRIX + IPV:KINRIX]  $\leq 1.5$ ).

## 14.2 Concomitant Vaccine Administration

In a U.S. study (Study 055) that enrolled children aged 4 to 6 years, KINRIX was administered concomitantly at separate sites with MMR vaccine (Merck & Co., Inc.) (n = 237) or with MMR vaccine and varicella vaccine (Merck & Co., Inc.) (n = 239). Immune responses to the antigens contained in KINRIX were measured approximately 1 month (28 to 48 days) after vaccination. Booster responses to diphtheria, tetanus, and pertussis antigens and GMTs for poliovirus (Type 1, 2, and 3) after the receipt of KINRIX administered concomitantly with MMR vaccine and varicella vaccine were non-inferior to immune responses following concomitant administration of KINRIX administered with MMR vaccine.

## 15 REFERENCES

1. Vitek CR and Wharton M. Diphtheria Toxoid. In: Plotkin SA, Orenstein WA, and Offit PA, eds. *Vaccines*. 5th ed. Saunders; 2008:139-156.
2. Wassilak SGF, Roper MH, Kretsinger K, and Orenstein WA. Tetanus Toxoid. In: Plotkin SA, Orenstein WA, and Offit PA, eds. *Vaccines*. 5th ed. Saunders; 2008:805-839.
3. Department of Health and Human Services, Food and Drug Administration. Biological products; Bacterial vaccines and toxoids; Implementation of efficacy review; Proposed rule. *Federal Register*. December 13, 1985;50(240):51002-51117.
4. Centers for Disease Control and Prevention. General Recommendations on Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR*. 2006;55(RR-15):1-48.
5. Sutter RW, Pallansch MA, Sawyer LA, et al. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: Poliovirus vaccination. In: Williams JC, Goldenthal KL, Burns DL, Lewis Jr BP, eds. Combined vaccines and simultaneous administration. Current issues and perspectives. New York, NY: The New York Academy of Sciences; 1995:289-299.

## 16 HOW SUPPLIED/STORAGE AND HANDLING

KINRIX is available in 0.5 mL single-dose, disposable, prefilled TIP-LOK syringes (Luer Lock syringes) packaged without needles. TIP-LOK syringes are to be used with Luer Lock compatible needles. The tip cap and rubber plunger stopper of the prefilled syringe are not made with natural rubber latex.

Prefilled syringe: NDC 58160-812-43

Package of 10 prefilled syringes: NDC 58160-812-52

Store refrigerated between 2° and 8°C (36° and 46°F). Do not freeze. Discard if the vaccine has been frozen. Protect prefilled syringes from light.

## 17 PATIENT COUNSELING INFORMATION

Provide the following information to the parent or guardian:

- Inform of the potential benefits and risks of immunization with KINRIX.
- Inform about the potential for adverse reactions that have been temporally associated with administration of KINRIX or other vaccines containing similar components.
- Give the Vaccine Information Statements, which are required by the National Childhood Vaccine Injury Act of 1986 to be given prior to immunization. These materials are available free of charge at the Centers for Disease Control and Prevention (CDC) website ([www.cdc.gov/vaccines](http://www.cdc.gov/vaccines)).

INFANRIX, KINRIX, PEDIARIX, and TIP-LOK are trademarks owned by or licensed to the GSK group of companies. The other brand listed is a trademark owned by or licensed to its respective owner and is not owned by or licensed to the GSK group of companies. The maker of this brand is not affiliated with and does not endorse the GSK group of companies or its products.



Manufactured by **GlaxoSmithKline Biologicals**

Rixensart, Belgium, U.S. License 1617, and

**GSK Vaccines GmbH**

Marburg, Germany, U.S. License 1617

Distributed by **GlaxoSmithKline**

Durham, NC 27701

©2026 GSK group of companies or its licensor.

KNX:20PI